<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03844360</url>
  </required_header>
  <id_info>
    <org_study_id>Antineoplastic Drugs001</org_study_id>
    <nct_id>NCT03844360</nct_id>
  </id_info>
  <brief_title>Dose Individualization of Antineoplastic Drugs and Anti-Infective Drug in Children With Hematoplastic Disease</brief_title>
  <official_title>Dose Individualization of Antineoplastic Drugs and Anti-Infective Drug in Children With Hematoplastic Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wei Zhao</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shandong University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators' purpose was to assess the feasibility of dosage individualization of the
      commonly used antineoplastic drugs and anti-infective drugs in children with hematoplastic
      disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators' purpose was to assess the feasibility of dosage individualization of the
      commonly used antineoplastic drugs and anti-infective drugs based on the opportunistic
      sampling strategy in children with confirmed or suspected hematological neoplasms.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 31, 2016</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change of plasma concentration of bortezomib</measure>
    <time_frame>at(0-0.5)h,(0.5-3)h,(24-48)h,(48-72)h hours after administration</time_frame>
    <description>To detect the plasma concentrations of bortezomib after administration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>change of plasma concentration of eltrombopag</measure>
    <time_frame>at (0.5-3)h,(3-6)h,(10-14)h,(20-24)h hours after oral administration</time_frame>
    <description>To detect the plasma concentrations of eltrombopag after administration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>change of plasma concentration of imatinib</measure>
    <time_frame>at (0.5-2)h,(2-4)h,(10-14)h,(20-24)h hours after oral administration</time_frame>
    <description>To detect the plasma concentrations of imatinib after administration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>change of plasma concentration of dasatinib</measure>
    <time_frame>at(0-0.5)h,(0.5-3)h,(10-14)h,(20-24)h hours after oral administration</time_frame>
    <description>To detect the plasma concentrations of dasatinib after administration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>change of plasma concentration of pegaspargase</measure>
    <time_frame>at Day-1,Day(0-1),Day(3-5),Day(8-10),Day(13-14) after administration</time_frame>
    <description>To detect the plasma concentrations of pegaspargase after administration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>plasma concentration of anti-infective drug</measure>
    <time_frame>through study completion, an average of 14 days</time_frame>
    <description>To detect the plasma concentrations of anti-infective drug after administration</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">1500</enrollment>
  <condition>Hematological Neoplasms</condition>
  <arm_group>
    <arm_group_label>Antineoplastic Drugs and Anti-infective Drugs</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bortezomib;eltrombopag;imatinib;dasatinib, pegaspargase and anti-infective drugs administered at standard dose for children with hematological neoplasms.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bortezomib</intervention_name>
    <description>bortezomib was administered follow the doctor's advice.</description>
    <arm_group_label>Antineoplastic Drugs and Anti-infective Drugs</arm_group_label>
    <other_name>Velcade</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eltrombopag</intervention_name>
    <description>eltrombopag was administered follow the doctor's advice.</description>
    <arm_group_label>Antineoplastic Drugs and Anti-infective Drugs</arm_group_label>
    <other_name>promacta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imatinib</intervention_name>
    <description>imatinib was administered follow the doctor's advice.</description>
    <arm_group_label>Antineoplastic Drugs and Anti-infective Drugs</arm_group_label>
    <other_name>Gleevec</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dasatinib</intervention_name>
    <description>dasatinib was administered follow the doctor's advice.</description>
    <arm_group_label>Antineoplastic Drugs and Anti-infective Drugs</arm_group_label>
    <other_name>sprycel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pegaspargase</intervention_name>
    <description>pegaspargase was administered follow the doctor's advice.</description>
    <arm_group_label>Antineoplastic Drugs and Anti-infective Drugs</arm_group_label>
    <other_name>Oncaspar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anti-Infective Drugs</intervention_name>
    <description>anti-infective drugs was administered follow the doctor's advice.</description>
    <arm_group_label>Antineoplastic Drugs and Anti-infective Drugs</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PEGylated Recombinant Human Granulocyte Colony-Stimulating Factor</intervention_name>
    <description>pegaspargase was administered follow the doctor's advice.</description>
    <arm_group_label>Antineoplastic Drugs and Anti-infective Drugs</arm_group_label>
    <other_name>PEG-rhG-CSF</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must be diagnosed with hematological neoplasms

          -  Antineoplastic drugs or anti-infective drugs used as part of regular treatment

        Exclusion Criteria:

          -  expected survival time less than the treatment cycle;

          -  patients with other factors that researcher considers unsuitable for inclusion.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wei Zhao, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shandong University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wei Zhao, Ph.D</last_name>
    <phone>86053188383308</phone>
    <email>zhao4wei2@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yan H Shi, Ph.D</last_name>
    <phone>86053188383308</phone>
    <email>zhao4wei2@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>State Key Laboratory of Experimental Haematology, Department of Paediatric Haematology, Institute of Haematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College</name>
      <address>
        <city>Tanjin</city>
        <state>Tianjin</state>
        <zip>300020</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>February 12, 2019</study_first_submitted>
  <study_first_submitted_qc>February 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 18, 2019</study_first_posted>
  <last_update_submitted>January 7, 2020</last_update_submitted>
  <last_update_submitted_qc>January 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Shandong University</investigator_affiliation>
    <investigator_full_name>Wei Zhao</investigator_full_name>
    <investigator_title>Professor; Head of department of clinical pharmacy and pharmacology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hematologic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bortezomib</mesh_term>
    <mesh_term>Imatinib Mesylate</mesh_term>
    <mesh_term>Dasatinib</mesh_term>
    <mesh_term>Pegaspargase</mesh_term>
    <mesh_term>Sargramostim</mesh_term>
    <mesh_term>Lenograstim</mesh_term>
    <mesh_term>Anti-Infective Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

